Noteworthily, the combination of anti-CSF1R antibody with the agonist anti-CD40 antibody led to a synergistic induction of proinflammatory macrophage polarization and the activation of CD8+ T cells, resulting in the regression of several transplanted tumor models (e.g., colon, sarcoma, and breast cancer) [112]. Here, CSF1R is linked to sarcoma.